Phase 2
Completed N=17
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Multiple Indications Cancer
Source: ClinicalTrials.gov NCT02297139 ↗
Enrolled (actual)
17
Serious AEs
47.1%
Results posted
May 2023
Primary outcomePrimary: Number of Participants Who Received Dasatinib Treatment — 1; 16 Participants
Summary
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Received Dasatinib Treatment |
1; 16 | — |
| PRIMARY Duration of Treatment |
25.3; 55.9 | — |
| SECONDARY Number of Participants With Adverse Events |
1; 15 | — |
| SECONDARY Number of Participants With Serious Adverse Events |
0; 8 | — |
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria
- Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol
- Receiving dasatinib at the time of signature of informed consent
- Males and Females, ages 18 and older
Exclusion Criteria
- All patients previously discontinued from a dasatinib study for any reason
- Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
- History of allergy to dasatinib
Data sourced from ClinicalTrials.gov (NCT02297139). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.